Labels: ,

CROs in China Published ($)

Posted by Steven Ma on November 17, 2012
Just got word that Issue 4 of the Journal of Commercial Biotechnology (JCB) has been published. I'm really excited about this because my final class project for Yali Friedman's class turned into a full-blown publication in a peer-reviewed journal. It was among the accepted articles and is featured in this issue.
It's amazing how much one can learn from writing about a subject - then publishing it. I thought that learning about the contract research organization industry in China might come in handy one day for expansion of R&D into eastern Asia, and decided to go the whole way. My experience has been thus - it's one thing thinking you know something, and another showing your knowledge and views for the world to see and critique. Looking forward to any correspondence from readers on the topic.

Here's the abstract, with the link to the article link. This may be good background knowledge for people interested in healthcare research in China.

Contract research organization (CRO) outsourcing has become a critical strategy for multinational biopharmaceutical companies looking to reduce costs, time-to-market and expanding their pipelines as blockbuster patents expire. Much of the growth in the CRO industry is coming from emerging markets, such as China and India. China's CRO industry began in 1996 and is still relatively young and fragmented. However, it is growing quickly at an annual rate of 30%. Global CRO giants such as Quintiles, PPD, Covance, Parexel and ICON have invested in facilities in China and some Chinese CROs have grown to become global players. This paper will provide a detailed analysis on CROs in China, including the characterization of companies and services provided, recent IPO/M&A deal activity, trends in the sector, and intellectual property and regulatory issues to consider. Readers will be able to obtain a clear picture of China's CRO landscape. This paper should serve as a guide for companies considering outsourcing R&D to China and investors looking for opportunities in China's CRO industry.

No comments :

Post a Comment

Subscribe to: Post Comments ( Atom )